At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 140 enrolled
Drug / intervention
Algeron +1 moredrug
Likely dose
Algeron 1.5 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC "BIOCAD", Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
In Brief
A Phase 3 clinical trial evaluating Algeron and PegIntron for Hepatitis and 2 related conditions. Completed, enrolled 140 participants across 6 sites.
Detailed Summary
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1 infected patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedApr 2014
Primary CompletionAug 2015
TodayJul 2026
First PostedApr 3, 2014
Enrollment StartJun 6, 2013
Primary CompletionAug 26, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.2 years ago
Interventions
Algerondrug
1.5 µg/kg of body weight subcutaneously, once a week
PegIntrondrug
1.5 µg/kg of body weight subcutaneously, once a week